Blood Peptidome-Degradome Profile of Breast Cancer

Journal Article · Mon Oct 18 00:00:00 EDT 2010 · PLoS One, 5(10):Article No.: e13133

DOI:https://doi.org/10.1371/journal.pone.0013133· OSTI ID:1000129

Shen, Yufeng; Tolic, Nikola; Liu, Tao; Zhao, Rui; Petritis, Brianne O; Gritsenko, Marina A; Camp, David G; Moore, Ronald J; Purvine, Samuel O; Esteva, FJ; Smith, Richard D

We report on the degradomic-peptidomic insights into blood plasma of early-stage breast cancer patients. The plasmin-α₂-antiplasmin and thrombin-antithrombin systems are observed to be changed in early stage breast cancer through the selective degradation of their functional domains. The extracellular matrix (ECM) protection protein complexes are destroyed, but the ECM itself is not massively degraded. Key innate immune system components and cancer inhibitor and suppressor substrates are differentially degraded. The degradomic-peptidomic analysis provides information on the selectivity and extent of substrate and functional domain degradation and the specificity of substrate cleavages, potentially enabling discovery of diagnostic and therapeutic targets for early-stage breast cancer.

• Research Organization: Pacific Northwest National Laboratory (PNNL), Richland, WA (US), Environmental Molecular Sciences Laboratory (EMSL)
• Sponsoring Organization: USDOE
• DOE Contract Number: AC05-76RL01830
• OSTI ID: 1000129
• Report Number(s): PNNL-SA-70095; 24698; 400412000
• Journal Information: PLoS One, 5(10):Article No.: e13133, Journal Name: PLoS One, 5(10):Article No.: e13133 Journal Issue: 10 Vol. 5
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
99 GENERAL AND MISCELLANEOUS
BLOOD
BLOOD PLASMA
Environmental Molecular Sciences Laboratory
FUNCTIONALS
MAMMARY GLANDS
NEOPLASMS
PATIENTS
PROTEINS
SPECIFICITY
SUBSTRATES
TARGETS